Published in Exp Cell Res on June 15, 1997
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol (1999) 3.15
Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol (1998) 2.89
The role of vascular endothelial growth factor in wound healing. J Surg Res (2008) 2.68
Relationship between RPE and choriocapillaris in age-related macular degeneration. Invest Ophthalmol Vis Sci (2009) 2.40
Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther (2008) 1.77
Human hepatic sinusoidal endothelial cells can be distinguished by expression of phenotypic markers related to their specialised functions in vivo. World J Gastroenterol (2006) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol (2000) 1.38
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol (2002) 1.31
Upregulated hypoxia inducible factor-1alpha and -2alpha pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther (2003) 1.20
Heat shock protein 70, heat shock protein 32, and vascular endothelial growth factor production and their effects on lipopolysaccharide-induced apoptosis in porcine aortic endothelial cells. Cell Stress Chaperones (2005) 0.91
Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia (2001) 0.90
Angiogenesis and lymphangiogenesis as prognostic factors after therapy in patients with cervical cancer. Contemp Oncol (Pozn) (2012) 0.85
STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin. J Biol Chem (2015) 0.82
Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clin Exp Metastasis (2002) 0.80
Expression of tumor necrosis factor-alpha and vascular endothelial growth factor in different zones of fetal membranes: a possible relation to onset of labor. J Mol Histol (2014) 0.75
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell (1992) 4.90
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med (1992) 4.39
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev (1993) 3.96
Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol (1994) 3.76
Inducer T lymphocytes synthesize a factor that stimulates proliferation of cloned mast cells. Nature (1981) 3.71
Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol (1989) 3.44
Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res (1990) 3.35
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res (1993) 2.98
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol (1995) 2.96
Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest (2000) 2.92
Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol (1993) 2.85
Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75
Cutaneous basophil hypersensitivity. II. A light and electron microscopic description. J Exp Med (1970) 2.61
Neutrophils emigrate from venules by a transendothelial cell pathway in response to FMLP. J Exp Med (1998) 2.61
Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res (1999) 2.55
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 2.54
Cytochemical localization of certain phosphatases in Escherichia coli. J Bacteriol (1970) 2.43
Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta (1989) 2.40
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. Am J Pathol (2001) 2.38
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J Exp Med (1996) 2.26
Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol (1991) 2.26
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res (1995) 2.24
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Cutaneous basophil hypersensitivity. I. A new look at the Jones-Mote reaction, general characteristics. J Exp Med (1970) 2.21
Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol (1979) 2.15
The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. J Leukoc Biol (1996) 2.15
Regulation of extravascular coagulation by microvascular permeability. Science (1985) 2.11
Fibronectin and fibrin provide a provisional matrix for epidermal cell migration during wound reepithelialization. J Invest Dermatol (1982) 2.10
Osteopontin expression and distribution in human carcinomas. Am J Pathol (1994) 2.09
Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell (1992) 2.00
Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer (2009) 2.00
Purification and properties of two acid phosphatase fractions isolated from osmotic shock fluid of Escherichia coli. Biochemistry (1967) 1.96
Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy (1984) 1.94
Mast cell clones: a model for the analysis of cellular maturation. J Cell Biol (1982) 1.91
Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol (1971) 1.84
Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res (1995) 1.79
Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst (1979) 1.79
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med (2001) 1.77
Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75
Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res (1993) 1.71
Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70
Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68
Expression of Tie1, Tie2, and angiopoietins 1, 2, and 4 in Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (2000) 1.68
Fibroblast migration in fibrin gel matrices. Am J Pathol (1993) 1.64
Tumor shedding and coagulation. Science (1981) 1.64
Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation (2001) 1.64
Pathways of macromolecular tracer transport across venules and small veins. Structural basis for the hyperpermeability of tumor blood vessels. Lab Invest (1992) 1.57
Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost (1997) 1.56
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol (1997) 1.56
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst (1995) 1.55
Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest (1996) 1.50
Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Ophthalmol (1996) 1.48
Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. Am J Pathol (1995) 1.47
Ultrastructural identification of the mouse basophil. Blood (1982) 1.47
Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol (1993) 1.46
Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol (1988) 1.44
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol (1995) 1.43
Fibronectin in delayed-type hypersensitivity skin reactions: associations with vessel permeability and endothelial cell activation. J Immunol (1981) 1.42
Ultrastructural localization of the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-expressing tumors and adenoviral vectors. J Histochem Cytochem (2000) 1.41
Loss of cell surface material from peritoneal exudate cells associated with lymphocyte-mediated inhibition of macrophage migration from capillary tubes. Lab Invest (1972) 1.41
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Vascular permeability factor mRNA and protein expression in human kidney. Kidney Int (1992) 1.40
Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J Invest Dermatol (1995) 1.39
Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys (1993) 1.39
Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation (1999) 1.38
Cellular and vascular manifestations of cell-mediated immunity. Hum Pathol (1986) 1.37
Cutaneous basophilic hypersensitivity: a new interpretation of the Jones-Mote reaction. J Immunol (1969) 1.36
Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J Invest Dermatol (1982) 1.35
Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev (1983) 1.34
Cloning of DLM-1, a novel gene that is up-regulated in activated macrophages, using RNA differential display. Gene (1999) 1.34
Fibrinogen/fibrin on the surface of macrophages: detection, distribution, binding requirements, and possible role in macrophage adherence phenomena. J Exp Med (1975) 1.33
Lipid bodies: cytoplasmic organelles important to arachidonate metabolism in macrophages and mast cells. J Immunol (1983) 1.33
Antigen-induced IgE-mediated degranulation of human basophils. Lab Invest (1980) 1.32
Metallo-enzymes released from Escherichia coli by osmotic shock. II. Evidence that 5'-nucleotidase and cyclic phosphodiesterase are zinc metallo-enzymes. J Biol Chem (1968) 1.32
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol (1995) 1.30
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res (1983) 1.29
Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J Histochem Cytochem (1999) 1.27
Chemotaxis of basophils by lymphocyte-dependent and lymphocyte-independent mechanisms. J Immunol (1975) 1.26
Role of the basophilic leukocyte in allograft rejection. J Immunol (1971) 1.26
Biochemical and cytochemical evidence for the polar concentration of periplasmic enzymes in a "minicell" strain of Escherichia coli. J Bacteriol (1970) 1.25
Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol (1996) 1.23
Fibrinogen influx and accumulation of cross-linked fibrin in mouse carcinomas. Cancer Res (1988) 1.23
Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest (1979) 1.22
Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med (1971) 1.21
Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst (1981) 1.20
Antigen-induced stimulation of glucosamine incorporation by guinea pig peritoneal macrophages in delayed hypersensitivity. J Exp Med (1972) 1.20
Degranulation of basophilic leukocytes in allergic contact dermatitis reactions in man. J Immunol (1976) 1.18
Immunologic rejection of diethylnitrosamine-induced hepatomas in strain 2 guinea pigs: participation of basophilic leukocytes and macrophage aggregates. J Exp Med (1973) 1.18
The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol (1976) 1.18
Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis (1989) 1.17